AZD-9291 (Mesylate)

• Post Date:

  Jun 06,2020

• Expiry Date:

  Jun 06,2021

• Detailed Description:

  Cas No. :1421373-66-1 Quantity: 1Metric Tons
  Specs:99%min
  Osimertinib mesylate Basic information
  Product Name: Osimertinib mesylate
  Synonyms: Mesylate-AZD9291;Osimertinib Mesylate (Tagrisso, Mereletinib, AZD-9291);Osimertinib d6;N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate;Osimertinib methanesulfonate;Osimertinib (AZD9291) mesylate;Mereletinib mesylate, 98%, a potent and selective mutated forms EGFR inhibitor;AZD-9291 mesylate (Osimertinib mesylate
  CAS: 1421373-66-1
  MF: C28H33N7O2.CH4O3S
  MW: 595.71298
  EINECS: 200-064-1
  Product Categories: API;AZD09
  Mol File: 1421373-66-1.mol
  Osimertinib mesylate Structure
  Osimertinib mesylate Chemical Properties
  Safety Information
  HS Code 29339900
  MSDS Information
  Osimertinib mesylate Usage And Synthesis
  Definition ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of osimertinib and methanesulfonic acid. Used for treatment of EGFR T790M mutation positive non-small cell lung cancer.
  Indications The collection of ibrutinib (Imbruvica(R), Pharmacyclics Inc.), afatinib, and osimertinib represents the small, yet expanding, group of covalent SMKIs. Ibrutinib is a non-receptor Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed chronic lymphocytic leukemia. Afatinib, approved for NSCLC in 2013 and squamous NSCLC in 2016, is a second-generation irreversible EGFR inhibitor that targets wild-type EGFR, the mutant T790M EGFR, and HER2. Osimertinib (AZD9291), which was approved by FDA in November 2015, is a third-generation irreversible EGFR inhibitor that selectively targets the mutant T790M EGFR. Rociletinib, which shares a high degree of structural similarity with that of osimertinib, is a promising covalent EGFR inhibitor developed by Clovis Oncology aimed for the treatment of patients with EGFR T790M-mutated NSCLC, until the company terminated its development in May 2016 following a negative vote fromthe FDA’sOncologic Drugs Advisory Committee.

• CAS Registry Number:

  1421373-66-1

• Synonyms:

  ;Osimertinib mesylate;N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1);Osimertinib Mesylate;AZD-9291 mesylate;

• Molecular Formula:

  C₂₈H₃₃N₇O₂.CH₄O₃S

• Molecular Weight:

  595.71

• Molecular Structure:

  

• Company:

  shanghai missyou chemical co.,ltd.         

• Contact:

  eileen zhang

• Tel:

  +86-18101936766

• Fax:

  021-58583907

• Email:

  eileen@shmychem.com